Healthcare companies rose after earnings from one Big Pharma company.
Merck shares ticked up after the drug giant posted quarterly revenue ahead of Wall Street targets, lifted by growth in sales of its Keytruda cancer drug.
Bristol Myers Squibb shares fell after the drugmaker's earnings lagged some investors' expectations.
Germany's Merck KGaA is finally nearing a roughly $3.5 billion deal for SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 24, 2025 16:45 ET (20:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.